Oxford Biomedica Share News (OXB)
OXB Share
OXB Share
OXB Share
OXB Share
OXB
OXB Share
OXB Level 2
OXB Live
OXB Broker
OXB Directors
OXB Financial
OXB
OXB Short
OXB
Last checked at -
(Corrects para 3 to say EU (not U.S.) approval for Imfinzi)* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares ...
Read more(For a live blog on European stocks, type LIVE/ in an Eikon news window.)* FTSE 100 hit by strong pound, marks worst day since late July* Oxford Biomedica rises as AstraZeneca expands supply tie-up* British factory activity improves in August* Hom...
Read more
UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal
Read moreLONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact
Read more(Corrects currency in second paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supp...
Read more(Adds details on supply agreement, background)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a po...
Read moreLONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand
Read more(Corrects currency in first paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell t...
Read moreSept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 millio...
Read more
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.
Read moreIN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal
Read more(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.
Read moreLONDON BRIEFING: Ryanair Expect 60% Drop In Passengers In Current Year
Read more(Sharecast News) - A Covid-19 vaccine backed by AstraZeneca is producing positive results in initial trials, according to a report.
Read moreDIRECTOR DEALINGS: Oxford Biomedica Director's Associate Buys Shares
Read more
Last checked at